Compare Novartis AG (NVS) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance

Novartis AGTrade

NEOS S&P 500 High Income ETFTrade

Price performance (Past 24H)

Key statistics

Novartis AG vs NEOS S&P 500 High Income ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while NEOS S&P 500 High Income ETF trades at $53.44. The key difference: Novartis AG pays a 3.17% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.

	NVS	SPYI
Market Cap	$290.25B	—
Sector	Health	Income / Options Overlay
52-Week High	$168.62	$54.07
52-Week Low	$113.50	$47.98
Enterprise Value	$330.27B	—
Dividend Yield	3.17%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novartis AG

Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.

The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.

NEOS S&P 500 High Income ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 1 day agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 5 days agoBullish View details →

SPYI

SPYI ETF yields 12% but faces pressure as volatility drops and Treasury yields rise.24/7 Wall Street · 4 days agoNeutral View details →

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

About NEOS S&P 500 High Income ETF

SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.